Alkem Laboratories Limited — Investor Meet, 19-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Alkem Labs Q2 FY26 saw robust revenue of 4,001 Cr (+17.2% YoY) and EBITDA of 920.8 Cr (+22.3% YoY), with a 23% margin. India sales grew 12.4% (2,766 Cr), U.S. 28% (764.9 Cr), and non-U.S. 32.4% (424.1 Cr). Management expects India to outperform the market and projects FY26 EBITDA at 19.5-20%. New ventures like U.S. CDMO and Medtech are ramping up, incurring initial opex but targeting long-term growth. GLP-1 approval is awaited in India. The company aims for 1% annual margin improvement post-FY27. Management maintains a confident outlook.